We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,666 | 21:35:13 |
From May 2019 to May 2024
By Giulia Petroni
Novartis AG said Monday that it would proceed with a phase 3 clinical trial to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with Covid-19.
The Swiss biotech company said that it has reached an agreement with the U.S. Food and Drug Administration to proceed with the trial and that it plans to begin enrollment for this study within the next few weeks.
The trial will involve approximately 440 patients and will be conducted at more than a dozen sites in the U.S, Novartis said.
The company added it would make its hydroxychloroquine intellectual property available through nonexclusive voluntary licenses, appropriate waivers, or similar mechanisms.
Drug supply will be provided by its generic pharmaceuticals and biosimilars division Sandoz, Novartis said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
April 20, 2020 02:12 ET (06:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
